Moderna and Merck Announce mRNA-4157, an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA®, Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma following Complete Resection versus KEYTRUDA

By
Laurisa Dohm
-
0
55
In the overall intention-to-treat population, adjuvant treatment with mRNA-4157 in combination with KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival compared with KEYTRUDA alone.
[Merck]
Press Release